Carmody LC, Germain AR, VerPlank L, et al. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. J Biomol Screen. 2012;17(9):1204-10. doi:10.1177/1087057112458317
De Marchi T, Kuhn E, Dekker LJ, et al. Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. J Proteome Res. 2016;15(4):1230-42. doi:10.1021/acs.jproteome.5b01119
Sharabi K, Lin H, Tavares CDJ, et al. Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes. Cell. 2017;169(1):148-160.e15. doi:10.1016/j.cell.2017.03.001
Smith G, Gerszten RE. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease. Circulation. 2017;135(17):1651-1664. doi:10.1161/CIRCULATIONAHA.116.025446
Wang L, Yang Q, Jaimes A, et al. MightyScreen: An Open-Source Visualization Application for Screening Data Analysis. SLAS Discov. 2018;23(2):218-223. doi:10.1177/2472555217731983
Chan B, Cottrell JR, Li B, et al. Development of a high-throughput AlphaScreen assay for modulators of synapsin I phosphorylation in primary neurons. J Biomol Screen. 2014;19(2):205-14. doi:10.1177/1087057113505905
Hempel CM, Sivula M, Levenson JM, et al. A system for performing high throughput assays of synaptic function. PLoS One. 2011;6(10):e25999. doi:10.1371/journal.pone.0025999
Maji B, Gangopadhyay SA, Lee M, et al. A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9. Cell. 2019;177(4):1067-1079.e19. doi:10.1016/j.cell.2019.04.009
Niepel M, Hafner M, Duan Q, et al. Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nat Commun. 2017;8(1):1186. doi:10.1038/s41467-017-01383-w
Shapiro RS, Chavez A, Porter CBM, et al. A CRISPR-Cas9-based gene drive platform for genetic interaction analysis in Candida albicans. Nat Microbiol. 2018;3(1):73-82. doi:10.1038/s41564-017-0043-0